{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:59:07Z","timestamp":1781647147098,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Langenbecks Arch Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pancreatectomy with venous resection (PVR) for resectable pancreatic ductal adenocarcinoma (PDAC) may be preoperatively planned or intraoperatively required due to suspected vascular involvement. The prognostic impact of pathologically confirmed venous infiltration (PVI) in upfront PVR remains unclear. This study assesses such impact on overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who underwent upfront PVR for PDAC were identified from a prospectively maintained database across three high-volume institutions. Clinical and pathological variables, including PVI status, were collected. Survival outcomes and predictors were analyzed using Cox regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 295 patients underwent upfront PVR. Segmental end-to-end reconstruction (Type III) was the most common approach (69%). PVI was confirmed in 66% of cases. Adjuvant therapy was administered to 69% of patients. Median OS was 32 months for PVI-negative vs. 21.1 months for PVI-positive patients (HR 1.49, 95% CI: 1.02\u20132.17,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037). One- and three-year survival rates were significantly lower in the PVI-positive group. Among PVI-positive patients, OS was 7 months without adjuvant therapy and 29.5 months with, aligning with outcomes in PVI-negative patients who received adjuvant treatment (HR 1.51,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.104). Independent predictors of OS included PVI (HR 1.67), age\u2009\u2265\u200975 (HR 1.93), N2 status (HR 1.89), total pancreatectomy (HR 2.42) and adjuvant therapy (HR 0.33).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>More than one-third of patients undergoing upfront PVR for suspected venous infiltration are overtreated as they lack pathologically confirmed vessel involvement. Conversely, when PVI is present, survival is significantly impaired. The successful delivery of adjuvant chemotherapy in case of PVI ameliorates outcomes as in cases lacking venous involvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00423-026-04041-2","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:48:30Z","timestamp":1775713710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of pathologically confirmed venous infiltration during upfront pancreatectomy: multicenter survival analysis"],"prefix":"10.1007","volume":"411","author":[{"given":"Giampaolo","family":"Perri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Guastella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Antelmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Canitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zipeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mastrangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Jovine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Cillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marchegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"4041_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7\u201330. https:\/\/doi.org\/10.3322\/caac.21332","journal-title":"CA Cancer J Clin"},{"key":"4041_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM (2021) Pancreatic cancer: a review. JAMA 326:851\u2013862. https:\/\/doi.org\/10.1001\/jama.2021.13027","journal-title":"JAMA"},{"key":"4041_CR3","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT (2020) Pancreatic cancer. Lancet 395:2008\u20132020. https:\/\/doi.org\/10.1016\/S0140-6736(20)30974-0","journal-title":"Lancet"},{"key":"4041_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378:607\u2013620. https:\/\/doi.org\/10.1016\/S0140-6736(10)62307-0","journal-title":"Lancet"},{"key":"4041_CR5","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913\u20132921. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155","journal-title":"Cancer Res"},{"key":"4041_CR6","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.3390\/cancers15092584","volume":"15","author":"M S\u0142odkowski","year":"2023","unstructured":"S\u0142odkowski M, Wro\u0144ski M, Karkocha D et al (2023) Current approaches for the curative-intent surgical treatment of pancreatic ductal adenocarcinoma. Cancers (Basel) 15:2584. https:\/\/doi.org\/10.3390\/cancers15092584","journal-title":"Cancers (Basel)"},{"key":"4041_CR7","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.surg.2022.01.011","volume":"172","author":"P Addeo","year":"2022","unstructured":"Addeo P, Cusumano C, Dufour P, Av\u00e9rous G, Bachellier P (2022) Upfront versus resection after neoadjuvant chemotherapy for pancreatic adenocarcinomas with venous contact: comparative analysis of operative and survival outcomes. Surgery 172:702\u2013707. https:\/\/doi.org\/10.1016\/j.surg.2022.01.011","journal-title":"Surgery"},{"key":"4041_CR8","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1016\/S1470-2045(15)00463-5","volume":"17","author":"SG Barreto","year":"2016","unstructured":"Barreto SG, Windsor JA (2016) Justifying vein resection with pancreatoduodenectomy. Lancet Oncol 17:e118\u2013e124. https:\/\/doi.org\/10.1016\/S1470-2045(15)00463-5","journal-title":"Lancet Oncol"},{"key":"4041_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.pan.2022.05.001","volume":"22","author":"ES Zwart","year":"2022","unstructured":"Zwart ES, Yilmaz BS, Halimi A et al (2022) Venous resection for pancreatic cancer: a systematic review and meta-analysis. Pancreatology 22:803\u2013809. https:\/\/doi.org\/10.1016\/j.pan.2022.05.001","journal-title":"Pancreatology"},{"key":"4041_CR10","doi-asserted-by":"publisher","first-page":"e1291","DOI":"10.1097\/SLA.0000000000005444","volume":"277","author":"T Hackert","year":"2023","unstructured":"Hackert T, Klaiber U, Hinz U et al (2023) Portal vein resection in pancreatic cancer surgery. Ann Surg 277:e1291\u2013e1298. https:\/\/doi.org\/10.1097\/SLA.0000000000005444","journal-title":"Ann Surg"},{"key":"4041_CR11","doi-asserted-by":"publisher","first-page":"e27438","DOI":"10.1097\/MD.0000000000027438","volume":"100","author":"JELP Filho","year":"2021","unstructured":"Filho JELP, Tustumi F, Coelho FF et al (2021) The impact of venous resection in pancreatoduodenectomy: a systematic review and meta-analysis. Med (Baltim) 100:e27438. https:\/\/doi.org\/10.1097\/MD.0000000000027438","journal-title":"Med (Baltim)"},{"key":"4041_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/SLA.0000000000004267","volume":"272","author":"DA Raptis","year":"2020","unstructured":"Raptis DA, S\u00e1nchez-Vel\u00e1zquez P, Machairas N et al (2020) Defining benchmark outcomes for pancreatoduodenectomy with venous resection. Ann Surg 272:731\u2013737. https:\/\/doi.org\/10.1097\/SLA.0000000000004267","journal-title":"Ann Surg"},{"key":"4041_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld C, Ferrone CR, Katz MHG et al (2023) Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol 20:318\u2013337. https:\/\/doi.org\/10.1038\/s41571-023-00746-1","journal-title":"Nat Rev Clin Oncol"},{"key":"4041_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fonc.2020.00041","volume":"10","author":"QP Janssen","year":"2020","unstructured":"Janssen QP, O\u2019Reilly EM, van Eijck CHJ et al (2020) Neoadjuvant treatment in pancreatic cancer. Front Oncol 10:41. https:\/\/doi.org\/10.3389\/fonc.2020.00041","journal-title":"Front Oncol"},{"key":"4041_CR15","unstructured":"National Comprehensive Cancer Network (2024) NCCN guidelines: pancreatic adenocarcinoma. Version 1.2024"},{"key":"4041_CR16","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C et al (2015) ESMO guidelines for pancreatic cancer. Ann Oncol 26:v56\u2013v68. https:\/\/doi.org\/10.1093\/annonc\/mdv295","journal-title":"Ann Oncol"},{"key":"4041_CR17","doi-asserted-by":"publisher","first-page":"32600","DOI":"10.18632\/oncotarget.15938","volume":"8","author":"A Song","year":"2017","unstructured":"Song A, Liu F, Wu L et al (2017) Histopathologic tumor invasion of portal vein in PDAC. Oncotarget 8:32600\u201332607. https:\/\/doi.org\/10.18632\/oncotarget.15938","journal-title":"Oncotarget"},{"key":"4041_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1245\/s10434-016-5515-6","volume":"23","author":"F Mierke","year":"2016","unstructured":"Mierke F, Hempel S, Distler M et al (2016) Impact of portal vein involvement on metastatic pattern. Ann Surg Oncol 23:730\u2013736. https:\/\/doi.org\/10.1245\/s10434-016-5515-6","journal-title":"Ann Surg Oncol"},{"key":"4041_CR19","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1245\/s10434-016-5123-5","volume":"23","author":"G Ramacciato","year":"2016","unstructured":"Ramacciato G, Nigri G, Petrucciani N et al (2016) Pancreatectomy with mesenteric and portal vein resection for borderline resectable pancreatic cancer: multicenter study of 406 patients. Ann Surg Oncol 23:2028\u20132037. https:\/\/doi.org\/10.1245\/s10434-016-5123-5","journal-title":"Ann Surg Oncol"},{"key":"4041_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","volume":"155","author":"M Bockhorn","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M et al (2014) Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155:977\u2013988. https:\/\/doi.org\/10.1016\/j.surg.2014.02.001","journal-title":"Surgery"},{"key":"4041_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1365-2559.2009.03376.x","volume":"55","author":"F Campbell","year":"2009","unstructured":"Campbell F, Smith RA, Whelan P et al (2009) Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1\u00a0mm of a resection margin. Histopathology 55:277\u2013283. https:\/\/doi.org\/10.1111\/j.1365-2559.2009.03376.x","journal-title":"Histopathology"},{"key":"4041_CR22","unstructured":"Amin MB, Edge SB, Greene FL et al (eds) (2017) Exocrine pancreas. AJCC cancer staging manual, 8th edn. Springer, New York, pp 337\u2013350"},{"key":"4041_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien\u2013Dindo classification of surgical complications: five-year experience. Ann Surg 250:187\u2013196. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b13ca2","journal-title":"Ann Surg"},{"key":"4041_CR24","unstructured":"The jamovi project (2024) jamovi (Version 2.6.13) [Computer software]. Retrieved from https:\/\/www.jamovi.org"},{"key":"4041_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","volume":"160","author":"JL van Dam","year":"2022","unstructured":"van Dam JL, Janssen QP, Besselink MG et al (2022) Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer 160:140\u2013149. https:\/\/doi.org\/10.1016\/j.ejca.2021.10.023","journal-title":"Eur J Cancer"},{"key":"4041_CR26","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1245\/s10434-014-4304-3","volume":"22","author":"JR Delpero","year":"2015","unstructured":"Delpero JR, Boher JM, Sauvanet A et al (2015) Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal\u2013superior mesenteric vein resection still justified? A survey of the Association Fran\u00e7aise de Chirurgie. Ann Surg Oncol 22:1874\u20131883. https:\/\/doi.org\/10.1245\/s10434-014-4304-3","journal-title":"Ann Surg Oncol"},{"key":"4041_CR27","doi-asserted-by":"publisher","first-page":"e087","DOI":"10.1097\/AS9.0000000000000087","volume":"2","author":"F Giannone","year":"2021","unstructured":"Giannone F, Capretti G, Abu Hilal M et al (2021) Resectability of pancreatic cancer is in the eye of the observer: a multicenter, blinded, prospective assessment of interobserver agreement on NCCN resectability status criteria. Ann Surg Open 2:e087. https:\/\/doi.org\/10.1097\/AS9.0000000000000087","journal-title":"Ann Surg Open"},{"key":"4041_CR28","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1245\/s10434-017-5972-6","volume":"24","author":"K Ohgi","year":"2017","unstructured":"Ohgi K, Yamamoto Y, Sugiura T et al (2017) Is pancreatic head cancer with portal venous involvement really borderline resectable? Appraisal of an upfront surgery series. Ann Surg Oncol 24:2752\u20132761. https:\/\/doi.org\/10.1245\/s10434-017-5972-6","journal-title":"Ann Surg Oncol"},{"key":"4041_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006567","author":"D Henault","year":"2024","unstructured":"Henault D, Kunde H, Zatzman C et al (2024) Vascular resection for pancreas cancer: 10-year experience from a single high volume center. Ann Surg. https:\/\/doi.org\/10.1097\/SLA.0000000000006567","journal-title":"Ann Surg"},{"key":"4041_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pan.2014.11.003","volume":"15","author":"I Ozola Zalite","year":"2015","unstructured":"Ozola Zalite I, Zykus R, Gonzalez MF et al (2015) Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology 15:19\u201324. https:\/\/doi.org\/10.1016\/j.pan.2014.11.003","journal-title":"Pancreatology"},{"key":"4041_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0903230","volume":"362","author":"NA van der Gaag","year":"2010","unstructured":"van der Gaag NA, Rauws EA, van Eijck CH et al (2010) Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 362:129\u2013137. https:\/\/doi.org\/10.1056\/NEJMoa0903230","journal-title":"N Engl J Med"},{"key":"4041_CR32","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1245\/s10434-017-6281-9","volume":"25","author":"G Marchegiani","year":"2018","unstructured":"Marchegiani G, Andrianello S, Nessi C et al (2018) Neoadjuvant therapy versus upfront resection for pancreatic cancer: the actual spectrum and clinical burden of postoperative complications. Ann Surg Oncol 25:626\u2013637. https:\/\/doi.org\/10.1245\/s10434-017-6281-9","journal-title":"Ann Surg Oncol"},{"key":"4041_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/jso.27674","volume":"130","author":"DL Dillon","year":"2024","unstructured":"Dillon DL, Park JY, Mederos MA et al (2024) Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resection. J Surg Oncol 130:72\u201382. https:\/\/doi.org\/10.1002\/jso.27674","journal-title":"J Surg Oncol"},{"key":"4041_CR34","doi-asserted-by":"publisher","first-page":"e0295983","DOI":"10.1371\/journal.pone.0295983","volume":"19","author":"L Huan","year":"2024","unstructured":"Huan L, Yu F, Cao D et al (2024) Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: a systematic review and network meta-analysis of randomized controlled trials. PLoS ONE 19:e0295983. https:\/\/doi.org\/10.1371\/journal.pone.0295983","journal-title":"PLoS ONE"},{"key":"4041_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1245\/s10434-022-12566-1","volume":"30","author":"N Ikenaga","year":"2023","unstructured":"Ikenaga N, Miyasaka Y, Ohtsuka T et al (2023) A prospective multicenter phase II trial of neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer with arterial involvement. Ann Surg Oncol 30:193\u2013202. https:\/\/doi.org\/10.1245\/s10434-022-12566-1","journal-title":"Ann Surg Oncol"},{"key":"4041_CR36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/SLA.0000000000005132","volume":"274","author":"N Machairas","year":"2021","unstructured":"Machairas N, Raptis DA, Vel\u00e1zquez PS et al (2021) The impact of neoadjuvant treatment on survival in patients undergoing pancreatoduodenectomy with concomitant portomesenteric venous resection: an international multicenter analysis. Ann Surg 274:721\u2013728. https:\/\/doi.org\/10.1097\/SLA.0000000000005132","journal-title":"Ann Surg"}],"container-title":["Langenbeck's Archives of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00423-026-04041-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-026-04041-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-026-04041-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:39:37Z","timestamp":1781645977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00423-026-04041-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4041"],"URL":"https:\/\/doi.org\/10.1007\/s00423-026-04041-2","relation":{},"ISSN":["1435-2451"],"issn-type":[{"value":"1435-2451","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived by the Institutional Review Board of Universit\u00e0 degli Studi di Padova due to the retrospective nature of the study and the use of anonymized data, in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was waived due to the retrospective design and the use of anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}